Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Aug;32(4):250-4.
doi: 10.5114/pdia.2015.53320. Epub 2015 Aug 12.

Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritis

Magdalena M Pirowska  1 , Anna Goździalska  2 , Sylwia Lipko-Godlewska  1 , Aleksander Obtułowicz  1 , Joanna Sułowicz  1 , Katarzyna Podolec  1 , Anna Wojas-Pelc  1
Affiliations

Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritis

Magdalena M Pirowska et al. Postepy Dermatol Alergol. 2015 Aug.

Abstract

Introduction: The tumor necrosis factor (TNF-α) was initially described as lymphotoxin or cachectin. The discovery of therapies blocking the action of TNF-α, in 1988, started a new era in the therapy. One of often reported adverse effects related to the use of TNF-α antagonists is induction of the formation of autologous antibodies and antibodies neutralizing anti-TNF drugs. The development of anti-TNF-induced lupus or classical drug-induced lupus is more rarely reported.

Aim: To evaluate the presence and the level of anti-nuclear antibodies in patients with psoriasis and psoriatic arthritis and the influence of anti-TNF therapy used on the concentration of antinuclear antibody (ANA).

Material and methods: A total of 28 subjects were included in the study. 71.4% of subjects were diagnosed with psoriatic arthritis and 28.6% with plaque psoriasis.

Results: Among the patients with plaque psoriasis, the antinuclear antibodies were found in 25% of subjects and in 80% of patients with psoriatic arthritis. After the treatment an increase in the titer or appearance of antibodies was found in 66.7% in the infliximab group, 18.2% in the etanercept group and 54.7% in the adalimumab group. No subjects developed symptoms of drug-induced systemic lupus.

Conclusions: Our findings have shown that all anti-TNF therapies induced ANA in psoriatic arthritis and psoriatic patients. Considering a mild course of lupus induced by anti-TNF treatment and, usually intrinsic, resolution of symptoms, the biological therapy still appears as a safe treatment for patients.

Keywords: anti-tumor necrosis factor therapy; anti-tumor necrosis factor-induced lupus; drug-induced lupus; psoriasis; psoriatic arthritis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Antinuclear antibodies among the patients with psoriasis and psoriatic arthritis before anti-TNF treatment
Figure 2
Figure 2
Antinuclear antibodies in the group of patients treated with infliximab
Figure 3
Figure 3
Antinuclear antibodies in the group of patients treated with etanercept
Figure 4
Figure 4
Antinuclear antibodies in the group of patients treated with adalimumab
See this image and copyright information in PMC

References

    1. Lubecka-Macura A, Kohut M. TNF superfamily – mechanisms of action, biological functions and therapeutic possibilities. Prz Gastroenterol. 2010;5:303–9.
    1. Nedoszytko B, Sokołowska-Wojdyło M, Ruckemann-Dziurdzińska K, et al. Chemokines and cytokines network in the pathogenesis of the inflammatory skin diseases: atopic dermatitis, psoriasis and skin mastocytosis. Postep Derm Alergol. 2014;31:84–91. - PMC - PubMed
    1. Shabgah AG, Fattahi E, Shahneh FZ. Interleukin-17 in human inflammatory diseases. Postep Derm Alergol. 2014;31:256–61. - PMC - PubMed
    1. Szepietowski J, Adamski Z, Chodorowska G, et al. Guidelines of Polish Dermatological Society on the treatment of psoriasis vulgaris and arthropathic psoriasis (psoriatic arthritis) with biological drugs. Przegl Dermatol. 2010;97:1–13.
    1. Kolarz B, Targońska-Stępniak B, Darmochwał-Kolarz D, Majdan M. Autoimmune aspects of treatment with TNF-a inhibitors. Postepy Hig Med Dosw. 2007;61:478–84. - PubMed

LinkOut - more resources